FibroGen, Inc. (FGEN)

NASDAQ: FGEN · Real-Time Price · USD
0.3194
-0.0066 (-2.02%)
May 8, 2025, 4:00 PM EDT - Market closed
-2.02%
Market Cap 32.27M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
Shares Out 101.04M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 271,845
Open 0.3301
Previous Close 0.3260
Day's Range 0.3178 - 0.3301
52-Week Range 0.1800 - 1.7400
Beta 0.87
Analysts Strong Buy
Price Target 10.00 (+3,030.87%)
Earnings Date May 12, 2025

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 14, 2014
Employees 225
Stock Exchange NASDAQ
Ticker Symbol FGEN
Full Company Profile

Financial Performance

In 2024, FibroGen's revenue was $29.62 million, a decrease of -36.71% compared to the previous year's $46.80 million. Losses were -$47.58 million, -83.26% less than in 2023.

Financial Statements

Analyst Forecast

According to one analyst, the rating for FGEN stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target
$10.0
(3,030.87% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehens...

21 hours ago - GlobeNewsWire

FibroGen to Report First Quarter 2025 Financial Results

SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a...

3 days ago - GlobeNewsWire

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place Ap...

5 weeks ago - GlobeNewsWire

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Conference Call March 17, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - CEO David DeLucia - CFO Conference Call P...

7 weeks ago - Seeking Alpha

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2024 and provided an update on the company's recen...

7 weeks ago - GlobeNewsWire

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen ...

2 months ago - GlobeNewsWire

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

FibroGen Inc. FGEN stock is trading higher on Thursday. The company announced the sale of its China subsidiary to AstraZeneca Plc AZN for approximately $160 million.

Other symbols: AZN
2 months ago - Benzinga

FibroGen sells China unit to AstraZeneca in deal worth $160 million

FibroGen said on Thursday that it has sold its China unit to AstraZeneca for about $160 million.

Other symbols: AZN
2 months ago - Reuters

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.

2 months ago - GlobeNewsWire

FibroGen Appoints David DeLucia as Chief Financial Officer

SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The compa...

5 months ago - GlobeNewsWire

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

FibroGen, Inc. (NASDAQ:FGEN) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A & IR Thane Wettig - CEO Juan Graham - CFO Conference...

6 months ago - Seeking Alpha

FibroGen Reports Third Quarter 2024 Financial Results

SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2024 and provided an update on the company's recent developments.

6 months ago - GlobeNewsWire

FibroGen to Report Third Quarter 2024 Financial Results

SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also con...

6 months ago - GlobeNewsWire

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David DeLucia - CFA Vice President, Corporate FP&A & Investor Relations Thane Wettig - Chi...

9 months ago - Seeking Alpha

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

FibroGen Inc. FGEN saw its share price plummet after the release of topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in pancreatic cancer patients.

10 months ago - Benzinga

FibroGen to Report Second Quarter 2024 Financial Results

SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also condu...

10 months ago - GlobeNewsWire

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen, Inc. top-line data from the phase 2/3 PanCAN Precision Promise study, using pamrevlumab for the treatment of patients with metastatic pancreatic cancer, expected mid-2024. Topline data from ...

1 year ago - Seeking Alpha

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen's immuno-oncology a...

1 year ago - GlobeNewsWire

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND)...

1 year ago - GlobeNewsWire

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

SAN FRANCISCO, May 23, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study c...

1 year ago - GlobeNewsWire

FibroGen to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company's management will participate in the following investor conferences:

1 year ago - GlobeNewsWire

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Conference Call May 6, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A and IR Thane Wettig - CEO Deyaa Adib - CMO Juan Graham - C...

1 year ago - Seeking Alpha

FibroGen Reports First Quarter 2024 Financial Results

SAN FRANCISCO, May 06, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2024 and provided an update on the company's recent developments.

1 year ago - GlobeNewsWire

FibroGen to Report First Quarter 2024 Financial Results

SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a...

1 year ago - GlobeNewsWire

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination wi...

1 year ago - GlobeNewsWire